| Literature DB >> 25796053 |
Peter Nordbeck1, Georg Ertl1, Oliver Ritter2.
Abstract
Magnetic resonance imaging (MRI) has long been regarded a general contraindication in patients with cardiovascular implanted electronic devices such as cardiac pacemakers or cardioverter defibrillators (ICDs) due to the risk of severe complications and even deaths caused by interactions of the magnetic resonance (MR) surrounding and the electric devices. Over the last decade, a better understanding of the underlying mechanisms responsible for such potentially life-threatening complications as well as technical advances have allowed an increasing number of pacemaker and ICD patients to safely undergo MRI. This review lists the key findings from basic research and clinical trials over the last 20 years, and discusses the impact on current day clinical practice. With 'MR-conditional' devices being the new standard of care, MRI in pacemaker and ICD patients has been adopted to clinical routine today. However, specific precautions and specifications of these devices should be carefully followed if possible, to avoid patient risks which might appear with new MR technology and further increasing indications and patient numbers.Entities:
Keywords: Cardiac pacemaker; Cardiovascular magnetic resonance imaging; ICD; Implantable cardioverter defibrillator; MRI conditional devices; MRI safety
Mesh:
Year: 2015 PMID: 25796053 PMCID: PMC4475571 DOI: 10.1093/eurheartj/ehv086
Source DB: PubMed Journal: Eur Heart J ISSN: 0195-668X Impact factor: 29.983
Clinical trials of magnetic resonance imaging in pacemaker patients
| Field strength | Trial | No. of patients | Adverse events |
|---|---|---|---|
| 0.2 | Strach | 114 | – |
| 0.5 | Sommer | 18 | Reed switch activation, continuous pacing in the static field |
| Valhaus | 32 | Decrease in battery voltage, reed switch activation | |
| Gimbel | 5 | One power-on-reset | |
| 1.5 | Martin | 54 | Significant threshold changes in 9% of leads |
| Gimbel | 10 | Seven patients had alterations in pacing thresholds | |
| Sommer | 82 | Increased capture threshold. In 4/115 patients troponin increased | |
| Nazarian | 31 (55 total) | – | |
| Mollerus | 32 (37 total) | – | |
| Naehle | 47 | Repetitive scans (171 examinations in 47 patients) caused decreased pacing capture, battery voltage | |
| Mollerus | 105 (127 total) | Decreased sensing amplitudes and impedances | |
| Halshtok | 9 (18 total) | Five power-on-resets | |
| Burke | 24 (38 total) | – | |
| Buendia | 28 (33 total) | Two temporary communication failures, one sensing error, one safety signal | |
| Nazarian | 237 (438 total) | Two power-on-resets, significant changes in lead parameters | |
| Cohen | 69 (109 total) | Decreases in battery voltage in 4%, pacing threshold increases in 3%, impedance changes in 6% | |
| Boilson | 32 | 5× power-on-reset, 3× asynchronous pacing | |
| 2.0 | Del Ojo | 13 | – |
| 3.0 | Naehle | 44 | – |
| Gimbel[ | 14 | – |
Clinical trials of magnetic resonance imaging in implantable cardioverter defibrillator patients
| Field strength | Trial | No. of patients | Adverse events |
|---|---|---|---|
| 1.5 | Coman | 11 | One short asymptomatic pause in pacing during scanning, One power-on-reset |
| Gimbel | 7 | One power-on-reset | |
| Nazarian | 24 (55 total) | – | |
| Mollerus | 5 (37 total) | – | |
| Pulver | 8 | – | |
| Mollerus | 22 (127 total) | Decreased sensing amplitudes and impedances | |
| Halshtok | 9 (18 total) | – | |
| Burke | 14 (38 total) | – | |
| Buendia | 5 (33 total) | One sensing error | |
| Nazarian | 201 (438 total) | One power-on-reset, changes in pacing threshold | |
| Cohen | 40 (109 total) | Decreases in battery voltage, pacing threshold increases, and impedance changes |